Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Don't fool yourself ...
View:
Post by MrMugsy on Oct 12, 2022 8:44am

Don't fool yourself ...

The market isn't going to understand the full value of what's going on here - IMO.
They're going to need analysts to explain it to them.  Hahaha !

Everything is back on the table - in a big way (it seems).

This is why it's been hard to get information out of these guys.
Lots of science on the go and they can't talk about it until a patent is issued.
As I've been saying - even the commercial study is going to be wrong - the numbers will be too low for the potential of this drug going forward (IMO).

If I am to guess, I'd say we're moving to a (higher purity) Naproxen - only a guess.  There are other potential ways but I'd assume they come with greater testing requirements.  To be seen.

I think this also puts 352 in question as well - might be able to do double duty if we're lucky.  TBD.  

Good Luck !
Comment by MrMugsy on Oct 12, 2022 2:34pm
One potential direction as I've followed in the recent past (but there are others too) ... "...we evaluated the efficacy of a new H2S-releasing derivative of naproxen, named naproxen-4-hydroxybenzodithioate (naproxen-HBTA), in reducing metastatic melanoma features, both in vitro and in vivo. The novel H2S donor has been prepared following a synthetic scheme that provided ...more  
Comment by Wriggles on Oct 12, 2022 6:12pm
https://clinmedjournals.org/articles/ijmnr/international-journal-of-medical-nano-research-ijmnr-5-023.php   I would expect the new chemical formulation to be similar to the original, otherwise, past study/trial results might not be acceptable for NDA purposes.    From the NR:     “Over the summer, we made significant advances with a faster-dissolving ...more  
Comment by MrMugsy on Oct 12, 2022 7:12pm
Yes - well said Wriggles The more and more we think about it, the smaller the change must be - in order to continue from here. I know of the partner you are talking - certainlly his interest is in synthetic design. There are a number of ways to attack and the one you mention is very realistic in this situation. Fingers crossed that it is a small change with large benefits to the drug.
Comment by StockingUp21 on Oct 12, 2022 7:41pm
Way to call every last thing you pumped wrong mugoo
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities